Humasis Co

Humasis Co Deferred Tax Liabilities

The Deferred Tax Liabilities of Humasis Co (205470.KQ) as of Nov 10, 2026 is 28.00 M KRW. In the previous year, Deferred Tax Liabilities was 43.00 M KRW — a change of -34.88% (lower).

Deferred Tax Liabilities

28.00 MKRW

YoY

-34.88%

Last updated:

Deferred Tax Liabilities of Humasis Co is 2016 28.00 M KRW. Deferred Tax Liabilities of Humasis Co was 2015 43.00 M KRW. It decreases by -34.88% lower compared to the previous year.

The Humasis Co Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2014
52.00 M KRW
Jan 1, 2015
43.00 M KRW
Jan 1, 2016
28.00 M KRW
The Humasis Co Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
28.00 MKRW-34.88%
43.00 MKRW-17.31%
52.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Deferred Tax Liabilities of Humasis Co is 28.00 M KRW in 2016.

Deferred Tax Liabilities of Humasis Co changed from 43.00 M KRW to 28.00 M KRW, representing a -34.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Humasis Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Humasis Co